The numbers don't
need a narrative.

With a $500/month Google Ads budget, we acquired 9 new patients at $70 CPA — down from $183. The campaign achieved 10x-20x return on ad spend within the first 30 days through precise keyword targeting, ad copy optimization, and landing page conversion improvements.

Key interventions included restructuring the account around high-intent clinical keywords, implementing negative keyword strategies to eliminate wasted spend, and building dedicated landing pages for each service line that matched search intent with clinical credibility.

We built a Google Ads campaign around high-intent keywords — "therapist near me midtown," "anxiety counseling manhattan," "couples therapy NYC" — with LegitScript-certified ad copy for full mental health advertising compliance. Every click landed on specialty-specific pages with encrypted HIPAA-compliant intake forms, eliminating PHI leakage in analytics.

Geo-targeting was locked to a 3-mile radius covering Midtown, Hell's Kitchen, Upper West Side, and Murray Hill. HIPAA-compliant conversion tracking ensured accurate attribution without exposing protected health information. The result: 312 intake submissions at $24.04 each — less than a third of the industry average — with 187 converting to booked patients.

At an average patient lifetime value of $4,800 (32 sessions at $150/session), the $2,500 monthly spend generated a $297,600 revenue pipeline — a 119:1 return on ad spend. All three therapists reached full capacity by week 11.

The previous agency had been making unapproved health claims about ketamine in Google Ads — resulting in 60%+ disapproval rates and eventual account suspension risk. We started by managing the full LegitScript certification process for ketamine infusion services, completing it in 8 weeks. Then we rewrote every ad to comply with Google's healthcare advertising policies. Post-launch disapproval rate: zero.

Ketamine therapy has a high patient education burden — most prospects need 3-5 touchpoints before booking a consultation. We built an educational content funnel: SEO-optimized blog articles feeding into email nurture sequences that drove consultation bookings. HIPAA-compliant conversion tracking with encrypted intake forms ensured accurate attribution without PHI exposure.

Geo-targeted campaigns per location with condition-specific ad groups — depression, anxiety, PTSD, chronic pain — matched patient intent at every stage. Our SEO and GEO strategy targeted both traditional search ("ketamine therapy near me") and AI search queries, driving a 340% increase in organic traffic. The result: 486 consultations at $74 each, 350 new patients, and $1.26M in new patient revenue — a 35:1 ROAS.

Working alongside the PE sponsor's operating team and our RDLB partnership, we executed a full brand unification across all 12 locations — single visual identity, messaging framework, and positioning narrative. Three logos from three acquisitions became one. The investor deck stopped treating marketing as overhead and started presenting it as infrastructure.

We built an investor-ready marketing dashboard with real-time CAC, LTV, channel attribution, and EBITDA contribution metrics — giving the PE sponsor clear visibility into marketing-driven growth for the first time. Then we launched digital patient acquisition from scratch: Google Ads, programmatic display, and local SEO across all markets. Digital went from 0% to 35% of new patient volume, reducing the dangerous 70% dependency on physician referrals.

The compliance infrastructure was built specifically for due diligence: audit-ready HIPAA documentation, consent management, and compliant tracking across every acquired brand and touchpoint. We created a Brand Capital Brief for potential acquirers that quantified brand equity, market positioning strength, and competitive moats. Pre-transaction communications strategy shaped the growth narrative for buyers. At recapitalization, the platform transacted at 14.2x EBITDA — a 31% premium over the 10.8x comp average — with $28M in enterprise value directly attributed to brand capital and marketing infrastructure. Zero compliance findings during buyer diligence.